Imperial College London

—Accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience in medical affairs, clinical development, and drug development —Visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in areas of osteoarthritis, immunology, oncology, and neuroscience PALO ALTO, Calif., Oct. 29, 2024 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Jeymi Tambiah, MBChB, FRCS, MS, FAPCR, MFPM(Dis) as its chief medical officer. Dr. Tambiah is an accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience creating and leading strategies for medical affairs, clinical development, and drug development programs. He also brings deep experience in translational medicine, commercialization, and health outcomes research to Genascence. Continue Reading Jeymi Tambiah, Chief Medical Officer, Genascence "Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in the areas of osteoarthritis, immunology, oncology, and neuroscience and I am excited to welcome him to Genascence as our chief medical offer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence. "His experience includes all phases of drug development from bench through Phase 1-4 clinical studies and building elite high performance medical affairs teams. Jeymi's development and research expertise, particularly within the osteoarthritis research community, will be invaluable as we execute on our strategy to bring gene therapy to people suffering from prevalent musculoskeletal diseases." "Genascence is a company that is transforming how we treat debilitating musculoskeletal diseases like osteoarthritis by pioneering the development of gene therapy," said Dr. Tambiah. "I am thrilled to join this outstanding team under Tom's leadership and apply my knowledge and experience to advance our clinical program so that we can bring potentially curative therapies to patients in desperate need of better treatments." Before joining Genascence, Jeymi was senior vice president of clinical development and external innovation at Biosplice Therapeutics, a start-up biotech developing molecules modulating mRNA splicing in oncology, arthritis, and neurodegenerative diseases, where he was primarily responsible for clinical development, medical affairs, and external thoughtleader and scientific partnerships. Previously, Jeymi worked for UCB Pharma in various roles of increasing leadership within medical affairs, launching the TNF-inhibitor certolizumab pegol within the European Union, U.K., and U.S. across multiple immunology indications. Before his move into pharma, Jeymi trained and practiced in cardiothoracic surgery at Guys' and St. Thomas' Hospitals in London. Jeymi is very active in the osteoarthritis research community, with numerous research awards and publications, holding many committee appointments, and regularly presenting at international conferences. He is the North American representative for the Faculty of Pharmaceutical Medicine UK, and in this role is dedicated to supporting the education and mentoring of physicians in drug development. Jeymi earned his medical degree from the University of Manchester, UK, a doctorate degree in vascular biology from Imperial College London where he was a Wellcome Research Fellow, and a BSc (Hons) in medical science from the University of St. Andrews, UK. He is a fellow of the Royal College of Surgeons of England and Edinburgh, a member of Faculty of Pharmaceutical Physicians UK by Distinction, and a fellow of the Academy of Physicians in Clinical Research. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit . SOURCE Genascence WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Hospital quality reporting platform Pharos announced today the close of its oversubscribed $5M seed round led by Felicis with participation from General Catalyst, Moxxie and Y Combinator. Pharos will use the funds to grow its engineering team, allowing customers to report to new clinical quality registries and measure a wider range of process metrics. Founded in 2024 by a team of clinicians and AI researchers, Pharos automates clinical quality reporting for hospitals, enabling submission to state and national quality registries without manual abstraction. Additionally, by enabling automatic extraction of custom process metrics, Pharos helps quality teams identify the process failures that are contributing to patient harm, enabling action on issues like sepsis mortality, hospital-acquired infections, and pressure ulcers. "Today, hospitals spend thousands of hours manually abstracting metrics from unstructured medical records to fulfill registry reporting requirements and understand patient safety events," said Felix Brann, CEO and co-founder of Pharos. "This manual work is expensive, pulls clinical staff away from the front-line, and means that hospital teams get data long after patients are discharged. Pharos automates abstraction for quality reporting, letting hospitals report to new registries and track metrics that matter to them without adding to clinical reviewer backlogs. We give teams data in real-time, letting them take action on process gaps before they turn into patient harm." Brann was previously VP of Data Science at Vital. At Vital, he and Matthew Jones, CTO and co-founder, deployed live predictive AI into over 70 hospitals, integrating with every major electronic health record vendor. While trialing a sepsis model, they recognized the value AI could provide to hospital quality teams. Brann was previously VP of Quantitative Research at JP Morgan. He has published papers in major medical journals on sepsis prediction and medical record summarization using LLMs. Jones worked on the Orion Health EHR and grew M2X from inception to international expansion. The team is also joined by Dr. Alex Clarke, Head of Research, an MD with a PhD in Artificial Intelligence from Imperial College London. He worked as a medical AI researcher at Meta and experienced the time-consuming medical abstraction process firsthand during his time as a resident doctor. "When we met the Pharos team and learned about their deep expertise in both healthcare and AI, we knew we had to work with them," said Ryan Isono, Partner at Felicis. "The mundane areas of healthcare administration make up nearly $1 trillion in spend annually. Pharos uses AI to automate the manual process of hospital quality reporting, which is dramatically underinvested in and can have a huge impact on not just savings but patient safety, too. The platform automates manual data abstraction from medical records, enabling hospitals to identify and resolve process failures in real time. With their experience deploying AI in 70+ hospitals and publishing relevant research, we couldn't imagine a better team to tackle this problem." Numerous studies have shown that access to data and adherence to processes can have significant impacts on patient safety. The American College of Surgeons estimates that 60% of current surgical site infections are preventable with good process, and the same is true for many other patient harm events. Pharos' mission is to help hospitals prevent this harm before it happens. You can learn more about the company and the technology at Media Contact Ellie Tippett, KCPR [email protected] About Pharos Pharos automates hospital quality reporting and helps staff identify the root causes of avoidable harm. Their AI automates chart abstraction for quality registries and process adherence measures, reducing staff burden and providing data instantly, rather than weeks after discharge. You can't improve what you can't measure. Pharos enables quality teams to see where and why safety issues are happening in real time, enabling them to take action on issues like sepsis mortality, hospital acquired infections and pressure ulcers. Pharos is a mission-driven team of clinicians and AI researchers from Meta, J.P. Morgan and Orion Health. They recently raised $5m in funding from Felicis, General Catalyst, Moxxie and Y Combinator to enable hospital quality teams with AI. About Felicis Founded in 2006, Felicis is a venture capital firm investing in companies reinventing core markets, as well as those creating frontier technologies. Felicis focuses on early-stage investments and currently manages over $3B in capital across 9 funds. The firm is an early backer of more than 45 companies valued at $1B+. More than 100 of its portfolio companies have been acquired or gone public, including Adyen (IPO), Credit Karma (acq by Intuit), Cruise (acq by General Motors), Fitbit (IPO), Guardant Health (IPO), Meraki (acq by Cisco), Ring (acq by Amazon), and Shopify (IPO). The firm is based in Menlo Park and San Francisco in California. Learn more at felicis.com. SOURCE Pharos WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies // CPD- and CME-accredited event highlights the need for renewed global efforts for tuberculosis controlVenlo, the Netherlands, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Thousands of healthcare professionals, advocates, and public policymakers from over 170 countries are set to participate from October 8-11 in the annual Global TB Summit, sponsored by QIAGEN, as the world confronts the resurgence of tuberculosis as one of the deadliest infectious diseases. After a decline of about 2% per year between 2020 and 2022, the tuberculosis incident rate rose by 3.9% in 2022. An estimated 10.6 million people worldwide fell ill with tuberculosis in 2022, leading to 1.3 million deaths. This made tuberculosis the second leading infectious disease killer after COVID-19.1 According to the World Health Organization (WHO), access to early and accurate diagnosis is a key factor for the End TB Strategy.1 One test endorsed by the WHO is QIAGEN’s leading TB blood test QuantiFERON-TB Gold Plus (QFT®-Plus), producing more accurate results than the century-old skin test. It is unaffected by prior BCG vaccination and is optimized to elicit both CD8 and CD4 T cell responses. With over 125 million tests distributed across more than 130 countries, QIAGEN’s QuantiFERON technology has been pivotal in national TB control strategies, aiding in the early detection and prevention of TB. “Tuberculosis remains a significant global threat, even though it is both preventable and curable. At the Global TB Summit 2024, we are focusing on the most pressing challenges. Our mission is clear: to harness innovation and foster global collaboration in our fight against this deadly disease. Only by coming together and leveraging our collective expertise can we seek to have a TB-free world,” said Glen Hansen, Chief Medical Officer at QIAGEN. This year’s Global TB Summit, scheduled in a hybrid format with virtual and in-person meetings in London, will gather to hear from over 35 leading TB experts about new ways to address the urgent need for intensified action against TB. The summit is free to attend online and offers participants the opportunity to earn CPD and CME credits. The event will cover critical topics such as global and regional TB updates, challenges in special populations, the impact of co-morbidities and the socioeconomic factors influencing TB. Attendees will also hear powerful personal narratives from patients and healthcare workers on the frontlines, providing both educational and inspirational content for all participants. Additionally, the event will cover advancements in TB diagnostics, prevention and treatment strategies. The identification and treatment of latent TB infection is critical to curbing the spread of the disease. An estimated one quarter of the world’s population is believed to be infected with latent TB. This makes the infection a silent threat, with those infected showing no symptoms of the disease. The infection can stay latent for years, but may progress to active TB in some patients, further transmitting and spreading the disease. QFT-Plus plays a crucial role in identifying those infected before they develop symptoms, enabling preventative treatment that can break the cycle of TB transmission. Professor Onn Min Kon, Consultant Respiratory Physician at Imperial College, England, and chair of the Global TB Summit, emphasized the event’s importance: "With a focus on the global challenges in TB control, as well as the latest advancements in diagnostics and new strategies in TB management, I am confident that this year’s Global TB Summit will offer invaluable insights that are directly applicable to your practice." With a history spanning more than a decade, the Global TB Summit has become a cornerstone event for learning about the latest developments in TB, networking with peers and gaining insights from real-world clinical cases. The full program as well as the registration form can be found here: https://tbsummit.qiagen.com/ 1) WHO Global Tuberculosis Report 2023 Factsheet, https://cdn.who.int/media/docs/default-source/hq-tuberculosis/global-tuberculosis-report-2023/global-tb-report-2023-factsheet.pdf?sfvrsn=f0dfc8a4_4&download=true; accessed on September 16, 2024 About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com. Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V.Category: Corporate